Ultivue Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
100
- Latest Deal Type
-
M&A
- Investors
-
2
Ultivue General Information
Description
Developer of multiplex biomarker assays designed to help in tissue phenotyping and digital pathology. The company's assays integrate validated antibodies, chemistry, advanced analytics, advanced exploration, and interrogation of tissue samples to drive personalized medicine, enabling researchers to quickly elucidate the complex phenotypes of the tumour immune microenvironment and advance research discoveries.
Contact Information
Website
www.ultivue.com(Operating Subsidiary)
Corporate Office
- 763D Concord Avenue
- Cambridge, MA 02138-1044
- United States
Corporate Office
- 763D Concord Avenue
- Cambridge, MA 02138-1044
- United States
Ultivue Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 09-Oct-2024 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 25-Jul-2024 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series AA) | 28-Apr-2023 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series D) | 22-Apr-2021 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C1) | 22-Sep-2020 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 28-Jun-2019 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 31-Jan-2018 | Completed | Generating Revenue | |||
| 3. Grant | 01-Jan-2016 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 21-Aug-2015 | $5.15M | $5.15M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2015 | Completed | Startup |
Ultivue Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C-1 | ||||||||
| Series C | ||||||||
| Series B | 15,100,668 | $0.000100 | $0.11 | $1.34 | $1.34 | $1.34 | 16.48% | |
| Series A | 5,150,000 | $0.000100 | $1 | $1 | $1 | 5.62% |
Ultivue Comparisons
Industry
Financing
Details
Ultivue Competitors (13)
One of Ultivue’s 13 competitors is Advanced Cell Diagnostics, a Formerly VC-backed company based in Minneapolis, MN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Advanced Cell Diagnostics | Formerly VC-backed | Minneapolis, MN | ||||
| Aspect Biosystems | Venture Capital-Backed | Vancouver, Canada | ||||
| VivoSim Labs | Formerly VC-backed | San Diego, CA | ||||
| FluoroFinder | Venture Capital-Backed | Broomfield, CO | ||||
| Cellmade | Private Equity-Backed | Ruffieux, France |
Ultivue Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ultivue Patents
Ultivue Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023279647-A1 | Methods and systems for removing a histological stain from a sample | Pending | 31-May-2022 | ||
| EP-4533057-A1 | Methods and systems for removing a histological stain from a sample | Pending | 31-May-2022 | ||
| US-20230408382-A1 | Methods and systems for removing a histological stain from a sample | Pending | 31-May-2022 | ||
| WO-2023235284-A1 | Methods and systems for removing a histological stain from a sample | Inactive | 31-May-2022 | ||
| EP-4085154-A1 | Methods for reducing nonspecific interactions on biological samples | Pending | 30-Dec-2019 | G01N33/533 |
Ultivue Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ultivue Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 120 Capital | Venture Capital | Minority | ||
| 6 Dimensions Capital | Venture Capital | Minority | ||
| ARCH Venture Partners | Venture Capital | Minority | ||
| Ally Bridge Group | Growth/Expansion | Minority | ||
| Applied Ventures | Corporate Venture Capital | Minority |
Ultivue FAQs
-
When was Ultivue founded?
Ultivue was founded in 2015.
-
Where is Ultivue headquartered?
Ultivue is headquartered in Cambridge, MA.
-
What is the size of Ultivue?
Ultivue has 100 total employees.
-
What industry is Ultivue in?
Ultivue’s primary industry is Other Healthcare Technology Systems.
-
Is Ultivue a private or public company?
Ultivue is a Private company.
-
What is Ultivue’s current revenue?
The current revenue for Ultivue is .
-
How much funding has Ultivue raised over time?
Ultivue has raised $115M.
-
Who are Ultivue’s investors?
120 Capital, 6 Dimensions Capital, ARCH Venture Partners, Ally Bridge Group, and Applied Ventures are 5 of 13 investors who have invested in Ultivue.
-
Who are Ultivue’s competitors?
Advanced Cell Diagnostics, Aspect Biosystems, VivoSim Labs, FluoroFinder, and Cellmade are some of the 13 competitors of Ultivue.
-
When was Ultivue acquired?
Ultivue was acquired on 09-Oct-2024.
-
Who acquired Ultivue?
Ultivue was acquired by Vizgen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
